| C10BX11 - Atorvastatin, Amlodipine and Perindopril | ATC-DDD Version 2016. Source: WHO | | C - Cardiovascular System | This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.
|
| | C10 - Lipid Modifying Agents | | | The DDDs are based on the treatment of hypercholesterolemia.
|
| | C10B - Lipid Modifying Agents, Combinations | Fixed combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B.
| For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.
|
| | C10BX - Lipid Modifying Agents in Combination with Other Drugs | This group comprises products which contain lipid modifying agents (including combinations of various lipid modifying agents) in combination with other substances.
Combinations with ACE inhibitors, angiotensin II antagonists, diuretics, beta blocking agents, or calcium channel blockers are classified here.
| The DDD for the fixed combination of rosuvastatin and valsartan is 1 UD (1 tablet), regardless of strength.
|
| | C10BX11 - Atorvastatin, Amlodipine and Perindopril |
|
|
|
